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NexusColorectal cancer (CRC), which has high prevalence in Saudi Arabia and worldwide, needs better understanding
by exploiting the latest available cytogenetic microarrays. We used biopsy tissue from consenting colorectal can-
cer patients to extract DNA and carry outmicroarray analysis using a CytoScan HD platform from Affymetrix. Pa-
tient speciﬁc comparisons of tumor–normal pairs were carried out. To ﬁnd out the high probability key players,
we performed Genomic Identiﬁcation of Signiﬁcant Targets in Cancer analysis and found 144 genes to form the
list of driver genes. Of these, 24 genes attained high GISTIC scores and suggest being signiﬁcantly associatedwith
CRC. Loss of heterozygosity and uniparental disomy were found to affect 9 genes and suggest different mecha-
nisms associated with CRC in every patient. Here we present the details of the methods used in carrying out
the above analyses. Also, we provide some additional data on biomarker analysis that would complement the
ﬁndings.
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c. This is an open access article undeExperimental design, materials and methods
We carried out patient speciﬁc comparison of tumor and normal sam-
ples. Each patient's tumor microarray proﬁle was compared against its
own normal proﬁle. Copy number variation, loss of heterozygosity and
uniparental disomy were studied and the affected genes were analyzed.
Sample collection
Biopsies were collected from Saudi Arabian patients presenting for
preliminary CRC diagnosis. All cases were collected regardless of surgi-
cal stage or histologic grade. Each hematoxylin and eosin (H&E) stained
case was reviewed by a board-certiﬁed pathologist to conﬁrm the
specimen's histological consistency with colon adenocarcinoma and
that adjacent normal specimen contained no tumor cells. The sections
were required to contain N60% tumor cell nuclei for inclusion in the
study. The cohort consisted of patients who have not undergone any
known CRC-related clinical intervention prior to the time of biopsy
acquisition. Multiple biopsies were taken from the normal and tumor
tissues. All the patient samples were collected from a single hospital.
Sample processing & DNA extraction
Paired samples of tumor and adjacent normal mucosa taken from
N2 cm apart were collected. Each tumor specimen weighed betweenr the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1.Agarose gel electrophoresis of PCR ampliﬁedDNA. Quality controlmeasure for checking ampliﬁed DNA requires running agarose gel. Representative samples from patient sampleswith
IDs 1M–8F (as mentioned in the original manuscript [3]) are provided here along with the positive sample as supplied in the CytoScan HD kit. Negative control is just water in place of DNA.
30 M.A. Aziz et al. / Genomics Data 2 (2014) 29–3110 and 30 mg. The biopsy tissue was stored in RNAlater (Ambion) at
4 °C for 24 h, followed by freezing and further storage at−20 °C [1].
CRC-positive sample pairs were then selected for DNA extraction by
NucleoSpin Trio Kit (Macherey-Nagel, Germany) [2]. 10–30 mg tissue
was homogenized using TissueLyser and stainless steel beads from
Qiagen. Quality and quantity checks were carried out by Nanodrop
(Thermo Fischer Scientiﬁc).
Data generation using cytogenetic array
CytoScan HD arrays along with a complete kit were acquired from
Affymetrix (Affymetrix Inc., USA). The recommended DNA ampliﬁca-
tion kit was obtained from Clontech (Clontech Laboratories Inc., USA).
The supplier's protocol was followed for the ampliﬁcation, hybridiza-
tion, washing and staining steps. Quality control after PCR ampliﬁcationFig. 2. Agarose gel electrophoresis of DNA after fragmentation step. Quality control for DNA af
mentioned in the original manuscript [3]) are provided here along with the positive sample as(Fig. 1) and fragmentation (Fig. 2) was carried out using agarose gel
electrophoresis. The arrays were scanned using a 30007G scanner
from Affymetrix.
Data analysis
We followed a case–control analysis strategy where the subject
served as the donor of both control and tumor tissues. The tumor–
normal comparisons were thus carried out between homogenous
samples.
CNV, LOH and UPD analyses
Nexus Copy Number 6.0 (Biodiscovery, Inc., CA, USA) was used to
assess genome wide copy number frequencies for the 15 patients.ter fragmentation step. Representative samples from patient samples with IDs 1M–8F (as
supplied in the CytoScan HD kit. Negative control is just water in place of DNA.
Table 1
Summary of processed samples.
Sample Data type Quality One copy gain One copy loss Two or more
copy gain
Two copy loss LOH Total CN aberrations
1M Affymetrix CEL 0.060 8 12 0 0 0 20
2M Affymetrix CEL 0.105 38 42 2 0 2 82
3F Affymetrix CEL 0.151 15 10 0 0 0 25
4F Affymetrix CEL 0.096 8 10 0 0 0 18
5F Affymetrix CEL 0.169 7 7 2 0 0 16
6F Affymetrix CEL 0.148 19 22 10 7 9 58
7M Affymetrix CEL 0.126 28 48 0 1 2 77
8F Affymetrix CEL 0.071 6 3 0 0 1 9
9F Affymetrix CEL 0.132 27 27 1 1 4 56
10F Affymetrix CEL 0.087 34 49 14 7 7 104
11F Affymetrix CEL 0.105 9 11 0 0 0 20
12M Affymetrix CEL 0.113 28 19 8 1 1 56
13M Affymetrix CEL 0.085 5 12 0 0 0 17
14F Affymetrix CEL 0.174 49 16 3 0 0 68
15M Affymetrix CEL 0.105 9 4 3 0 1 16
31M.A. Aziz et al. / Genomics Data 2 (2014) 29–31Furthermore, Aroma.affymetrix – another CBS implementation as part
of the BioConductor's DNACopy library and the associated TumorBoost
algorithm (which normalize allele speciﬁc copy numbers for tumor
samples with paired normal) – was also used to identify genomic
events. We obtained conforming results from both implementations.
The combination of CytoScanHD's high resolution and in depth analysis
by Nexus Copy Number allows us to capture even the smallest genomic
events. All the samples had a quality score of b0.2 (Table 1). The
frequency threshold parameters used for the analysis are 0.2 for gain,
0.6 for high gain,−0.2 for slight loss and−1.0 for big loss. A minimum
cutoff of 500 kb was used for detecting these events.Table 2
Biomarker molecules among the driver genes.
Biomarker gene Biomarker application
ADAM12 Diagnosis
AGR3 Diagnosis
AURKA Efﬁcacy
BCL2 Diagnosis, efﬁcacy, prognosis
CLDN7 Unspeciﬁed application
CRP Diagnosis, disease progression, efﬁcacy,
prognosis, safety
CYP19A1 Diagnosis, efﬁcacy
DCC Prognosis
EXO1 Diagnosis
FGFR2 Diagnosis, response to therapy
GSTM1 Diagnosis, efﬁcacy, safety
HLTF Diagnosis
ICAM1 Diagnosis, efﬁcacy, prognosis
IDO1 Disease progression, efﬁcacy, prognosis
IGF2BP3 Diagnosis
IL6 Diagnosis, disease progression, efﬁcacy,
prognosis, response to therapy, safety
IL6R Efﬁcacy
INHBA Diagnosis
INSR Prognosis
MGMT Diagnosis, efﬁcacy, prognosis
MS4A1 Efﬁcacy, prognosis
MUC4 Diagnosis, disease progression
OVGP1 Diagnosis
PTGS1 Efﬁcacy
PTK2 Diagnosis, disease progression, efﬁcacy,
prognosis
PTP4A3 Disease progression
SLC16A1 Diagnosis
SMAD4 Prognosis
STK11 Diagnosis
TP53 Diagnosis, disease progression, efﬁcacy,
prognosis, response to therapy
ZNF217 PrognosisInformation regarding transcription factor binding sites was obtained
from the Open Regulatory Annotation Database (ORegAnno, www.
oreganno.org).
miRNA target analysis was carried out using the microRNA integra-
tion system for target gene prediction (MIRSYSTEM) software version
20130328 available at http://mirsystem.cgm.ntu.edu.tw/.
GISTIC analysis
Combining GISTIC (Genomic Identiﬁcation of Signiﬁcant Targets in
Cancer) score ranking and peaks in copy numbers of genomic regions,
we identiﬁed the genes according to the annotation of the human
genome assembly GRCh37/hg19.
Through Nexus Copy Number, we carried out GISTIC analysis.
G-scores relay the signiﬁcance of genes to drive cancer by weighing
regions of aberration against the likelihood for random occurrence.
The G-scores for regions detected by CBS were examined. We labeled
as signiﬁcant any region of a score above 2.
Biomarker discovery
We analyzed 144 genes identiﬁed through GISTIC for their potential
role as biomarkers in human cancer. 31 genes were identiﬁed as poten-
tial biomarkers (Table 2). The full table of biomarker analysis with infor-
mation about expression in body ﬂuids is available as Supporting
Table 1.
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